Volrustomig is a monovalent bispecific immunotherapy and is strategically unique as it combines anti PD-1 and anti CTLA-4 action. Though technology and understanding of biological systems are advancing in astonishing pace, drug discovery remains a lengthy, expensive, difficult, and inefficient process with high attrition rate and low discovery rate. It is worthwhile to follow its development.

Contemporary literature and pharmaceutical new reports were studied to find the interesting and exciting story & events behind such development which mainstream clinical oncology journals always miss to capture.

Volrustomig is still not due for any full report excepting only a few early phase report. Hence, the circumstances through which the process of development passed is captured to record the facts.

This is real time story of what actually occurred in inventing and bringing this molecule in phase III.